Last checked at 24 Nov 2017 07:00
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Oncimmune Holdings plc ("Oncimmune" or the "Company")
Satisfaction of the condition under the Delayed Completion Placing
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT®platform technology announces that it has received confirmation from HMRC that the Ordinary Share are regarded as a qualifying holding for the purposes of Part 6 of the Income Tax Act 2007 (the "VCT Condition").
Consequently, the 833,333 Ordinary Shares that were conditionally placed as part of the placing of 4,166,667 Ordinary Shares announced on 27 September 2017 ("Delayed Completion Placing Shares") will now be issued at the placing price of £1.20.
Under the terms of the placing, admission of the Delayed Completion Placing Shares is to occur within 5 business days of satisfaction of the VCT Condition. Admission is therefore expected at 8.00 am on 28 November 2017.
Following Admission of the Delayed Completion Placing Shares, the Company's enlarged issued share capital will comprise 55,216,071 Ordinary Shares of 1 pence each with voting rights in the Company. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in the interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Giles Balleny, Hugh Kingsmill Moore
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0) 20 3709 5708